Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director | June 03, 2025 | June 04, 2025 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | President and COO | March 03, 2023 | March 08, 2023 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | October 26, 2023 | October 30, 2023 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | Director · President and CEO | July 10, 2017 | July 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 03, 2025 · Filed June 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,045 |
Reported balance
After 2025-06-03 transaction · row 1
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 60,000 · Balance 207,045 F1: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
Jazz Pharmaceuticals plc
Report date March 03, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,014 |
Ending reported balance
After 2023-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-03 · Grant · Acquired 13,456 · Balance 60,440 F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Row 2 · 2023-03-05 · Tax withholding · Disposed 5,426 · Balance 55,014 F2: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F2: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Protagonist Therapeutics, Inc
Report date October 26, 2023 · Filed October 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.21 · Expires 2033-10-26 | Direct | 45,000 |
Reported balance
After 2023-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-26 · Grant · Acquired 45,000 · Balance 45,000 F1: The options vest in 36 equal monthly installments following October 26, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 36 equal monthly installments following October 26, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Viracta Therapeutics, Inc.
Report date July 10, 2017 · Filed July 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.24 · Expires 2017-09-13 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-10 · Disposition to issuer · Disposed 4,306 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2019-08-31 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-10 · Disposition to issuer · Disposed 18,333 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.54 · Expires 2021-06-30 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-10 · Disposition to issuer · Disposed 118,435 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-10 · Disposition to issuer · Disposed 70,834 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.32 · Expires 2023-02-28 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-07-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2024-10-31 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-07-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2027-07-10 | Direct | 17,582 |
Reported balance
After 2017-07-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-07-10 · Grant · Acquired 17,582 · Balance 17,582 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F3: The option vests in monthly installments over three (3) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.30 · Expires 2024-02-28 | Direct | 0 |
Reported balance
After 2017-07-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-07-10 · Disposition to issuer · Disposed 50,001 · Balance 0 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
| Employee Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2027-07-10 | Direct | 240,177 |
Reported balance
After 2017-07-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-07-10 · Grant · Acquired 240,177 · Balance 240,177 F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F4: The option vests in monthly installments over two (2) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
F2: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share.
F3: The option vests in monthly installments over three (3) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
F4: The option vests in monthly installments over two (2) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2020 Filed Jun 5, 2020 23:02 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 15,961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034845 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,961 Underlying: Common Stock · 15,961 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The Restricted Stock Unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. F4 · derivative.expiration_date: The Restricted Stock Unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:02 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 34,001 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001209191-20-034845 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,001 Underlying: Common Stock · 34,001 shares Expires 2030-06-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The Option shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. Read SEC document |
| May 27, 2020 Filed May 29, 2020 23:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0000899243-20-014630 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 27, 2020 over a one-year period. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-20-014352 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $16.10 | $80,500.00 |
DisclosureSEC source: 0000899243-20-014352 · doc4.xml · nonDerivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,000 | $6.55 | $32,750.00 |
DisclosureSEC source: 0000899243-20-014352 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 23:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,735 | $124.50 | $216,007.50 |
DisclosureSEC source: 0001765581-20-000037 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,391 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 39,114 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000026 · edgardoc.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,114 Underlying: Ordinary Shares · 39,114 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 886 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000026 · edgardoc.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886 Underlying: Ordinary Shares · 886 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000026 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,126 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 29, 2020 Filed Feb 6, 2020 22:32 UTC | CERUS CORP CERS · Entity 5431 | PurchaseCommon Stock | 1,000 | $4.15 | $4,150.00 |
DisclosureSEC source: 0001209191-20-007230 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,910 Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 23:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 1,599 | $146.09 | $233,597.91 |
DisclosureSEC source: 0001765581-20-000004 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,126 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 140 ordinary shares and 73 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019 and November 29, 2019, respectively. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0000899243-19-017627 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 18, 2019 over a one-year period. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:37 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 13,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-035565 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,958 Underlying: Common Stock · 13,958 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit shall vest one year from the date of grant. F4 · derivative.expiration_date: The restricted stock unit shall vest one year from the date of grant. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:37 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 29,581 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-19-035565 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,581 Underlying: Common Stock · 29,581 shares Expires 2029-06-04 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document |
| June 05, 2019 Filed Feb 4, 2020 01:15 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 13,958 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006137 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,958 Underlying: Common Stock · 13,958 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit shall vest one year from the date of grant. F4 · derivative.expiration_date: The restricted stock unit shall vest one year from the date of grant. Read SEC document |
| June 05, 2019 Filed Feb 4, 2020 01:15 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 29,581 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-20-006137 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,581 Underlying: Common Stock · 29,581 shares Expires 2029-06-04 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document |
| June 04, 2019 Filed Jun 7, 2019 01:23 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 12,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-035352 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: This restricted stock unit vested on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. F2 · derivative.expiration_date: This restricted stock unit vested on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. Read SEC document |
| June 04, 2019 Filed Jun 7, 2019 01:23 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 12,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-035352 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 34,286 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000023 · edgardoc.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,286 Underlying: Ordinary Shares · 34,286 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 714 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000023 · edgardoc.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Underlying: Ordinary Shares · 714 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000023 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,512 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 00:07 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,604 | $126.01 | $202,120.04 |
DisclosureSEC source: 0001232524-19-000002 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,512 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 116 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2018. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023070 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| June 06, 2018 Filed Jun 22, 2018 22:57 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 12,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-039312 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,758 Underlying: Common Stock · 10,223 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. F4 · derivative.expiration_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2018 Filed Jun 22, 2018 22:57 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 20,466 | Not disclosed Strike: $6.77 | Not disclosed |
DisclosureSEC source: 0001209191-18-039312 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,466 Underlying: Common Stock · 16,399 shares Expires 2028-06-05 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2018 Filed Jul 11, 2018 21:14 UTC Amendment | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 12,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-042367 · doc4a.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,758 Underlying: Common Stock · 12,758 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. F4 · derivative.expiration_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2018 Filed Jul 11, 2018 21:14 UTC Amendment | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 24,014 | Not disclosed Strike: $6.77 | Not disclosed |
DisclosureSEC source: 0001209191-18-042367 · doc4a.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,014 Underlying: Common Stock · 24,014 shares Expires 2028-06-05 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2019 Annual Meeting of Stockholders. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 21:07 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 19,816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035785 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vested on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. F2 · derivative.expiration_date: The restricted stock unit vested on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 21:07 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 19,816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035785 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 42,160 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000047 · edgardoc.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,160 Underlying: Ordinary Shares · 42,160 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date, January 3, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 2,840 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000047 · edgardoc.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,840 Underlying: Ordinary Shares · 2,840 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date, January 3, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000047 · edgardoc.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of January 3, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantEmployee Stock Option(right to buy) · Derivative | 240,177 | Not disclosed Strike: $2.62 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 9 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,177 Underlying: Common Stock · 240,177 shares Expires 2027-07-10 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F4 · derivative.exercise_date: The option vests in monthly installments over two (2) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantEmployee Stock Option (right to buy) · Derivative | 17,582 | Not disclosed Strike: $2.62 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 8 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,582 Underlying: Common Stock · 17,582 shares Expires 2027-07-10 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F3 · derivative.exercise_date: The option vests in monthly installments over three (3) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $10.20 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 7 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-10-31 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,001 | Not disclosed Strike: $39.30 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 6 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,001 shares Expires 2024-02-28 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $31.32 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 5 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-02-28 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 70,834 | Not disclosed Strike: $10.44 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 4 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,834 shares Expires 2022-02-28 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 118,435 | Not disclosed Strike: $12.54 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,435 shares Expires 2021-06-30 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 18,333 | Not disclosed Strike: $17.64 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,333 shares Expires 2019-08-31 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:32 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 4,306 | Not disclosed Strike: $93.24 | Not disclosed |
DisclosureSEC source: 0001179110-17-010334 · edgar.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,306 shares Expires 2017-09-13 F2 · price: On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share. F1 · derivative.exercise_date: The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company. Read SEC document |
| June 07, 2017 Filed Jun 13, 2017 01:34 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 19,816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039325 · doc4.xml · derivative · entry 4 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,816 Underlying: Common Stock · 19,816 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F5 · derivative.exercise_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. F5 · derivative.expiration_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. Read SEC document |
| June 07, 2017 Filed Jun 13, 2017 01:34 UTC | CERUS CORP CERS · Entity 5431 | GrantOption Right to Buy · Derivative | 47,507 | Not disclosed Strike: $2.61 | Not disclosed |
DisclosureSEC source: 0001209191-17-039325 · doc4.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,507 Underlying: Common Stock · 47,507 shares Expires 2027-06-06 F3 · price: Not applicable. F4 · derivative.exercise_date: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2017 Filed Jun 13, 2017 01:34 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 12,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039325 · doc4.xml · derivative · entry 2 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. F2 · derivative.expiration_date: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2017 Filed Jun 13, 2017 01:34 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 12,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039325 · doc4.xml · nonDerivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $12.13 | $0.00 |
DisclosureSEC source: 0000899243-17-014586 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 24, 2017 over one-year period. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 19:22 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001179110-16-032351 · edgar.xml · derivative · entry 3 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2026-11-30 F3 · derivative.exercise_date: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020. Read SEC document |
| November 30, 2016 Filed Dec 6, 2016 19:36 UTC Amendment | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001179110-16-032503 · edgar.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2026-11-30 F1 · derivative.exercise_date: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.